- Home
- GLPI vs GMAB Comparison
GLPI vs GMAB Comparison
Compare GLPI & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPI
- GMAB
- Stock Information
- Founded
- GLPI 2013
- GMAB 1999
- Country
- GLPI United States
- GMAB Denmark
- Employees
- GLPI N/A
- GMAB N/A
- Industry
- GLPI Real Estate Investment Trusts
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- GLPI Real Estate
- GMAB Health Care
- Exchange
- GLPI Nasdaq
- GMAB Nasdaq
- Market Cap
- GLPI 13.0B
- GMAB 13.9B
- IPO Year
- GLPI N/A
- GMAB N/A
- Fundamental
- Price
- GLPI $45.81
- GMAB $21.42
- Analyst Decision
- GLPI Buy
- GMAB Buy
- Analyst Count
- GLPI 16
- GMAB 7
- Target Price
- GLPI $52.58
- GMAB $37.80
- AVG Volume (30 Days)
- GLPI 1.8M
- GMAB 968.5K
- Earning Date
- GLPI 07-24-2025
- GMAB 08-11-2025
- Dividend Yield
- GLPI 6.81%
- GMAB N/A
- EPS Growth
- GLPI N/A
- GMAB 276.80
- EPS
- GLPI 2.61
- GMAB 18.36
- Revenue
- GLPI $1,565,067,000.00
- GMAB $3,230,902,140.00
- Revenue This Year
- GLPI $5.19
- GMAB $21.64
- Revenue Next Year
- GLPI $3.54
- GMAB $15.57
- P/E Ratio
- GLPI $17.58
- GMAB $1.17
- Revenue Growth
- GLPI 5.38
- GMAB 25.43
- 52 Week Low
- GLPI $44.48
- GMAB $17.24
- 52 Week High
- GLPI $52.60
- GMAB $27.94
- Technical
- Relative Strength Index (RSI)
- GLPI 42.87
- GMAB 46.21
- Support Level
- GLPI $45.30
- GMAB $21.26
- Resistance Level
- GLPI $47.10
- GMAB $22.27
- Average True Range (ATR)
- GLPI 0.84
- GMAB 0.34
- MACD
- GLPI -0.08
- GMAB -0.11
- Stochastic Oscillator
- GLPI 20.82
- GMAB 11.50
About GLPI Gaming and Leisure Properties Inc.
Gaming and Leisure Properties Inc, or GLP, is a self-administered and self-managed Pennsylvania real estate investment trust (REIT). It is engaged in acquiring, financing, and owning real estate property to be leased to gaming operators in triple-net lease arrangements. Its portfolio consists of gaming and related facilities and amenities such as Ameristar Black Hawk, Bally's Casino, Argosy Casino Alton, Bally's Chicago, Hollywood Casino Aurora, and others located across different states in the United States.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.